Healthcare Industry News: Orthofix
News Release - February 9, 2012
Orthofix International Launches Centronail Ankle Compression Nailing and Lapidus Plating Systems in the U.S.LEWISVILLE, Texas--(Healthcare Sales & Marketing Network)--Orthofix International N.V., (NASDAQ:OFIX ) (the Company) announced today the full U.S. launch of two differentiated internal fixation repair solutions for the foot and ankle market with the Centronail Ankle Compression Nailing and Contours Lapidus Plating Systems.
Centronail Ankle Compression Nailing (ACN) System
With the U.S. launch of the Centronail Ankle Compression Nailing (ACN) System, Orthofix now has a differentiated solution for hindfoot fusions. This procedure treats patients who suffer from debilitating pain and incapacity as a result of arthritis, trauma, and diabetes. The ACN System fuses up to three joints in order to relieve pain and restore activity.
The ACN System’s unique two-piece targeting assembly allows for screw placement flexibility while ensuring improved stability and simplicity throughout the procedure. In addition, the ACN allows for independently controlled compression of the tibiotalar and subtalar joints. The precision, robustness, and flexibility with respect to this critical aspect of the procedure are unmatched within the industry.
Contours Lapidus Plating System (LPS)
While the ACN System represents the Company’s entry into the hindfoot internal fixation market, the Contours Lapidus Plating System (LPS) focuses on revision procedures and joint fusion in the small bones of the midfoot. The Lapidus surgical procedure is comprised of a tarsometatarsal (TMT) joint fusion to treat patients with debilitating pain and discomfort that typically accompanies hallux valgus (bunion deformities). The Contours LPS incorporates a plate design contoured specifically for the TMT anatomy and the anatomical forces at that joint, which leads to restoration of biomechanical properties and healing.
Orthofix’s President and Chief Executive Officer Robert Vaters stated, “The introduction of these two novel technologies highlights the Company’s commitment to the attractive U.S. foot and ankle market. While Orthofix has a strong presence in external fixation, the bolstering of its internal fixation offering along with its regenerative solutions creates an attractive and differentiated value proposition for both orthopedic surgeons and podiatrists.”
Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative repair and regenerative solutions to the spine and orthopedic markets. Orthofix’s products are widely distributed around the world to orthopedic surgeons and patients via Orthofix’s sales representatives and its subsidiaries, including BREG, Inc., and via collaborations with other leading orthopedic product companies. In addition, Orthofix is collaborating on R&D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, Texas Scottish Rite Hospital for Children, and the Cleveland Clinical Foundation. For more information about Orthofix, please visit www.Orthofix.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.